5'-methylthioinosine: MH METHYLTHIOINOSINE refers to 6-methylthioinosine [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
5'-S-methyl-5'-thioinosine : A 5'-deoxyribonucleoside consisting of inosine where the 5'-hydroxy group is substituted by a methylsulfanyl group. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
| ID Source | ID |
|---|---|
| PubMed CID | 135511888 |
| CHEBI ID | 48595 |
| SCHEMBL ID | 2228480 |
| MeSH ID | M0114673 |
| Synonym |
|---|
| 9-(5-s-methyl-5-thio-beta-d-ribofuranosyl)-9h-purin-6-ol |
| 5'-deoxy-5'-methylthioinosine |
| 5'-deoxy-5'-(methylsulfanyl)inosine |
| s-methyl-5'-thioinosine |
| CHEBI:48595 |
| 5'-s-methyl-5'-thioinosine |
| 5'-methylthioinosine |
| 17298-58-7 |
| 9-[(2r,3r,4s,5s)-3,4-dihydroxy-5-(methylsulfanylmethyl)oxolan-2-yl]-3h-purin-6-one |
| C19787 |
| 5-dmti |
| inosine, 5'-s-methyl-5'-thio- |
| SCHEMBL2228480 |
| 9-(5-s-methyl-5-thiopentofuranosyl)-9h-purin-6-ol |
| DTXSID80938256 |
| Q27121276 |
| 9-[(2r,3r,4s,5s)-3,4-dihydroxy-5-(methylsulfanylmethyl)oxolan-2-yl]-1h-purin-6-one |
| 5/'-methylthioinosine |
| Class | Description |
|---|---|
| inosines | Any purine ribonucleoside that is a derivative of inosine. |
| 5'-deoxyribonucleoside | |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 3 (42.86) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 2 (28.57) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 7 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||